Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
Satellos Recognized as a Top 50 TSX Venture Exchange Company
Satellos to Commence Trading on the Toronto Stock Exchange
Satellos Announces Preliminary Data in Facioscapulohumeral Muscular Dystrophy